Pre-Market Technical Scan on Healthcare Information Services Equities -- Teladoc, athenahealth, Evolent Health, and HealthEquity - iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Feb 20, 2018 7:20 AM ET

Pre-Market Technical Scan on Healthcare Information Services Equities — Teladoc, athenahealth, Evolent Health, and HealthEquity

Disclosure NewswireTM

iCrowdNewswire - Feb 20, 2018

NEW YORK,  — strives to bring the best free research to the investment community.  Today we are offering reports on TDOC, ATHN, EVH, and HQY which can be accessed for free by signing up to dedicates attention to the Healthcare Information Services industry, which includes software solutions, clinical content, hardware, and devices that offer health care providers secure access to clinical, administrative, and financial data that can be used to boost quality, improve safety, and increase efficiency across the sector. Lined up for monitoring this morning are: Teladoc Inc. (NYSE: TDOC), athenahealth Inc. (NASDAQ: ATHN), Evolent Health Inc. (NYSE: EVH), and HealthEquity Inc. (NASDAQ: HQY). All you have to do is sign up today for this free limited time offer by clicking the link below.


Last Friday, Purchase, New York headquartered Teladoc Inc.’s stock climbed slightly by 0.68%, to close the day at $37.15. A total volume of 518,361 shares was traded. The Company’s shares have advanced 18.69% in the last month, 32.44% in the previous three months, and 76.48% over the past year. The stock is trading 7.16% above its 50-day moving average and 12.99% above its 200-day moving average. Additionally, shares of Teladoc, which operates a telehealth platform that provides on-demand healthcare services to its members in the US, have a Relative Strength Index (RSI) of 60.47. 

On January 26th, 2018, research firm Jefferies initiated a ‘Buy’ rating on the Company’s stock.

On February 13th, 2018, Teladoc announced that it will release its Q4 and full-year 2017 results on February 27th, 2018, after the market closes. The Company will host a conference call at 4:15 p.m. E.T. on the same day to review the results. A live audio webcast of the call will be available on the Company’s investor website, under “Events & Presentations.” Get the full research report on TDOC for free by clicking below at:


Shares in Watertown, Massachusetts headquartered athenahealth Inc. saw a decline of 1.71%, finishing Friday’s session at $138.82. The stock recorded a trading volume of 372,244 shares. The Company’s shares have gained 10.59% in the last month, 11.04% over the previous three months, and 18.71% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.65% and 4.97%, respectively. Furthermore, shares of athenahealth have an RSI of 56.64. 

On February 07th, 2018, athenahealth announced that its Board of Directors has unanimously appointed Jeff Immelt, former GE chairman and CEO, as chairman, effective that day. Mr. Immelt is recognized for advancing digitization across industries, particularly for driving the first wave of digitization across healthcare enterprises and the Healthcare industry at large. Free research on ANTH can be accessed at:

Evolent Health

Arlington, Virginia headquartered Evolent Health Inc.’s stock finished flat at $14.25 last Friday at the close. A total volume of 498,565 shares was traded. The Company’s shares have advanced 3.26% in the past month and 32.56% in the previous three months. The stock is trading above its 50-day moving average by 4.40%. Additionally, shares of Evolent Health, which through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the US, headquartered have an RSI of 54.30. 

On February 09th, 2018, Evolent Health announced that it will release its Q4 and full-year 2017 operating results on February 27th, 2018, after market close, followed by a conference call at 5:30 p.m. ET. A live webcast of the conference call will be available under the investor relations section of the Company’s website. Visit now and sign up for the free research on EVH at:


Draper, Utah headquartered HealthEquity Inc.’s shares ended the session 0.27% higher at $54.86. The stock recorded a trading volume of 557,290 shares, which was above its three months average volume of 530,040 shares. The Company’s shares have advanced 13.35% in the last month, 10.03% over the previous three months, and 26.17% over the past year. The stock is trading 12.35% above its 50-day moving average and 13.39% above its 200-day moving average. Moreover, shares of HealthEquity have an RSI of 73.17. 

On February 09th, 2018, HealthEquity announced that its Executive Vice President of Operations, Jon Soldan, has been recognized as one of Utah Business’ Forty Under 40 honorees. This annual program honors the state’s up-and-coming professionals, who are rising through the ranks at record speed. The awards recognized innovating tech wizards, visionary entrepreneurs, non-profit leaders, and executive captains, who are guiding industry trends and shaping the future. The free technical report on HQY is available at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

Contact Information:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

View Related News >